Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events

References

• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850. doi:10.1016/j.jaad.2008.02.03918423260
   PubMed Web of Science ®Google Scholar
• Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–667. doi:10.1684/ejd.2012.180222910173
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.33923014338
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/S0140-6736(07)61128-317658397
   PubMed Web of Science ®Google Scholar
• Asadullah K, Sterry W, Trefzer U. Cytokines: interleukin and interferon therapy in dermatology. Clin Exp Dermatol. 2002;27(7):578–584.12464153
   PubMed Web of Science ®Google Scholar
• Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11–27. doi:10.1007/s00281-015-0539-826573299
   PubMed Web of Science ®Google Scholar
• Kerdel FA, Strober BE. Tumor necrosis factor inhibitors in psoriasis: an update. Semin Cutan Med Surg. 2014;33(2 Suppl 2):S31–S36. doi:10.12788/j.sder.006624979543
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1–70. doi:10.1111/j.1468-3083.2009.03389.x
   PubMed Web of Science ®Google Scholar
• Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol. 2013;133(8):1963–1970. doi:10.1038/jid.2013.7823426133
   PubMed Web of Science ®Google Scholar
• de Vries AC, Thio HB, de Kort WJ, et al. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. Br J Dermatol. 2017;176(3):624–633. doi:10.1111/bjd.1486727416891
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–1157. doi:10.1136/ard.2004.03226815677701
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4):1227–1236. doi:10.1002/art.2096715818699
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, van Hoogstraten HJ, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325–1334. doi:10.1111/bjd.1240423621698
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e31-15. doi:10.1016/j.jaad.2006.07.017
   PubMed Web of Science ®Google Scholar
• Kim WB, Marinas JE, Qiang J, Shahbaz A, Greaves S, Yeung J. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: a Canadian multicenter retrospective study. J Am Acad Dermatol. 2015;73(2):237–241. doi:10.1016/j.jaad.2015.04.02326026334
   PubMed Web of Science ®Google Scholar
• Kleyn CE, Griffiths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther. 2006;6(8):797–805. doi:10.1517/14712598.6.8.79716856801
   PubMed Web of Science ®Google Scholar
• Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159(3):527–536. doi:10.1111/j.1365-2133.2008.08728.x18627374
   PubMed Web of Science ®Google Scholar
• Wee JS, Petrof G, Jackson K, Barker JN, Smith CH. Infliximab for the treatment of psoriasis in the U.K.: 9 years’ experience of infusion reactions at a single centre. Br J Dermatol. 2012;167(2):411–416. doi:10.1111/j.1365-2133.2012.10931.x22404545
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98(6):1315–1324. doi:10.1111/j.1572-0241.2003.07457.x12818276
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Pandhi D, Khurana A. Biologics in dermatology: adverse effects. Int J Dermatol. 2015;54(12):1442–1460. doi:10.1111/ijd.1280226147909
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374. doi:10.1016/S0140-6736(05)67566-616226614
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–608. doi:10.1056/NEJMoa02088812584368
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2(7):542–553.15224278
   PubMed Web of Science ®Google Scholar
• Torii H, Nakano M, Yano T, Kondo K, Nakagawa H. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: results of the SPREAD study. J Dermatol. 2017;44(5):552–559. doi:10.1111/1346-8138.1369827882586
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–1231. doi:10.1136/gut.2006.09997817229796
   PubMed Web of Science ®Google Scholar
• Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol. 2006;118(1):11–19. doi:10.1016/j.clim.2005.07.01016125467
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–1050. doi:10.1016/j.jaad.2010.09.73421315483
   PubMed Web of Science ®Google Scholar
• Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3(3):148–155.12614731
   PubMed Web of Science ®Google Scholar
• Wallis RS. Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin North Am. 2011;25(4):895–910. doi:10.1016/j.idc.2011.08.00222054762
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60(7):1884–1894. doi:10.1002/art.2463219565495
   PubMed Web of Science ®Google Scholar
• Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum. 2008;58(4):947–952. doi:10.1002/art.2328518383389
   PubMed Web of Science ®Google Scholar
• Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–636. doi:10.1111/bjd.1566528513835
   PubMed Web of Science ®Google Scholar
• Doherty SD, Van Voorhees A, Lebwohl MG, et al. National psoriasis foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209–217. doi:10.1016/j.jaad.2008.03.02318485527
   PubMed Web of Science ®Google Scholar
• Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis. 2003;62(8):791. doi:10.1136/ard.62.8.79112860745
   PubMed Web of Science ®Google Scholar
• British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60(10):800–805. doi:10.1136/thx.2005.04679716055611
   PubMed Web of Science ®Google Scholar
• Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy. 2005;25(9):1181–1192. doi:10.1592/phco.2005.25.9.118116164393
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Sebastiani M, et al.; GISEA group. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Clin Exp Rheumatol. 2019;11.
   Web of Science ®Google Scholar
• Dogra S, Khullar G. Tumor necrosis factor-alpha antagonists: side effects and their management. Indian J Dermatol Venereol Leprol. 2013;79(Suppl 7):S35–S46. doi:10.4103/0378-6323.11552623974693
   PubMed Web of Science ®Google Scholar
• Poulalhon N, Begon E, Lebbe C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156(2):329–336. doi:10.1111/j.1365-2133.2006.07639.x17223874
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542. doi:10.1016/j.jaad.2004.02.02115389187
   PubMed Web of Science ®Google Scholar
• Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol. 2014;55(1):75–79. doi:10.1111/ajd.1205423651182
   PubMed Web of Science ®Google Scholar
• Poulin Y, Therien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg. 2010;14(2):100–104. doi:10.2310/7750.2009.0900720338127
   PubMed Web of Science ®Google Scholar
• Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–1017. doi:10.1016/j.jaad.2008.12.03119344980
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol. 2017;77(5):845–854.e845. doi:10.1016/j.jaad.2017.07.01328893407
   PubMed Web of Science ®Google Scholar
• Shear NH, Hartmann M, Toledo-Bahena M, et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol. 2014;171(3):631–641. doi:10.1111/bjd.1300424673357
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013;40(9):683–695. doi:10.1111/1346-8138.1223924033880
   PubMed Web of Science ®Google Scholar
• Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36(4):312–323. doi:10.1111/j.1365-2036.2012.05189.x22725726
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kalb RE, Blauvelt A, et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol. 2012;67(4):642–650. doi:10.1016/j.jaad.2011.10.02022153792
   PubMed Web of Science ®Google Scholar
• Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol. 2010;257(9):1421–1431. doi:10.1007/s00415-010-5591-720495815
   PubMed Web of Science ®Google Scholar
• Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890–901. doi:10.1111/bjd.1496427518205
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Kerdel F, Naldi L, et al. Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J Drugs Dermatol. 2017;16(10):1002–1013.29036254
   PubMed Web of Science ®Google Scholar
• Mössner R, Thaci D, Mohr J, et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch Dermatol Res. 2008;300(3):101–105. doi:10.1007/s00403-008-0831-818239925
   PubMed Web of Science ®Google Scholar
• Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179–e185. doi:10.1016/j.jaad.2011.05.03821752492
   PubMed Web of Science ®Google Scholar
• Sherlock ME, Walters T, Tabbers MM, et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr. 2013;56(5):512–518. doi:10.1097/MPG.0b013e31828390ba23274341
   PubMed Web of Science ®Google Scholar
• Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9(1):1–14. doi:10.2165/00128071-200809010-0000118092839
   PubMed Web of Science ®Google Scholar
• Adisen E, Aral A, Aybay C, Gurer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. J Dermatol. 2010;37(8):708–713. doi:10.1111/j.1346-8138.2010.00882.x20649712
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59(1):40–49. doi:10.1016/j.jdermsci.2010.04.01420547039
   PubMed Web of Science ®Google Scholar
• Bito T, Nishikawa R, Hatakeyama M, et al. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol. 2014;170(4):922–929. doi:10.1111/bjd.1279124329764
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40(1):39–42. doi:10.1111/j.1346-8138.2012.01679.x23039179
   PubMed Web of Science ®Google Scholar
• Balsa A, Sanmarti R, Rosas J, et al. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. Rheumatology (Oxford). 2018;57(4):688–693. doi:10.1093/rheumatology/kex47429365183
   PubMed Web of Science ®Google Scholar
• Kui R, Gal B, Gaal M, Kiss M, Kemeny L, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-alpha level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol. 2016;43(9):1018–1023. doi:10.1111/1346-8138.1330126892625
   PubMed Web of Science ®Google Scholar
• Torii H, Sato N, Yoshinari T, Nakagawa H. Dramatic impact of a psoriasis area and severity index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol. 2012;39(3):253–259. doi:10.1111/j.1346-8138.2011.01459.x22211581
   PubMed Web of Science ®Google Scholar
• Agency EM. Questions and answers on biosimilar medicines (similar biological medicinal products). EMA/837805/2011; 2012.
   Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316. doi:10.1016/S0140-6736(17)30068-528502609
   PubMed Web of Science ®Google Scholar
• Komaki Y, Yamada A, Komaki F, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017;79:4–16. doi:10.1016/j.jaut.2017.02.00328209290
   PubMed Web of Science ®Google Scholar
• Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:1. doi:10.1186/s13075-016-0981-626732314
   PubMed Web of Science ®Google Scholar
• Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. mAbs. 2014;6(5):1163–1177. doi:10.4161/mabs.3222125517302
   PubMed Web of Science ®Google Scholar
• Layegh Z, Ruwaard J, Hebing RCF, et al. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. Int J Rheum Dis. 2019;22:869–873. doi:10.1111/1756-185X.1351230767391
   PubMed Web of Science ®Google Scholar
• O’Toole A, Moss AC. Optimizing biologic agents in ulcerative Colitis and Crohn’s disease. Curr Gastroenterol Rep. 2015;17. doi:10.1007/s11894-015-0453-1
   PubMedGoogle Scholar
• Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(4):736–739. doi:10.1016/j.jaad.2016.04.06827473452
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bianchi L, Conti A, et al. Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2017;177(6):e325–e326. doi:10.1111/bjd.1565928498543
   PubMed Web of Science ®Google Scholar
• Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord. 2015;16:166.26205000
   PubMed Web of Science ®Google Scholar
• Pink AE, Fonia A, Allen MH, Smith CH, Barker JN. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2010;162(4):780–785. doi:10.1111/j.1365-2133.2009.09563.x19863499
   PubMed Web of Science ®Google Scholar
• Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol. 2011;165(6):1355–1358. doi:10.1111/j.1365-2133.2011.10555.x21801160
   PubMed Web of Science ®Google Scholar
• Reich K, Griffiths C, Barker J, et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology. 2008;217(3):268–275. doi:10.1159/00014997018685261
   PubMed Web of Science ®Google Scholar
• Luber AJ, Tsui CL, Heinecke GM, Lebwohl MG, Levitt JO. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. J Am Acad Dermatol. 2014;70(3):525–532. doi:10.1016/j.jaad.2013.10.05924388425
   PubMed Web of Science ®Google Scholar
• Vena G, Loconsole F, Mastrandrea V, Buquicchio R, Cassano N. Therapeutic hotline: re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis. Dermatol Ther. 2010;23(2):199–202. doi:10.1111/j.1529-8019.2010.01315.x20415828
   PubMed Web of Science ®Google Scholar
• Dalaker M, Bonesronning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol. 2009;23(3):277–282. doi:10.1111/j.1468-3083.2008.03039.x19207642
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38(4):321–334.21544940
   PubMed Web of Science ®Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165(5):1109–1117. doi:10.1111/j.1365-2133.2011.10615.x21910713
   PubMed Web of Science ®Google Scholar